185 related articles for article (PubMed ID: 19169632)
21. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
[TBL] [Abstract][Full Text] [Related]
23. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Ross LL; Weinberg WG; DeJesus E; Fischl MA; Horton JH; Pappa KA; Lancaster CT; Pakes GE; Smith KY
AIDS Res Hum Retroviruses; 2010 Apr; 26(4):407-17. PubMed ID: 20380480
[TBL] [Abstract][Full Text] [Related]
24. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
Gantner P; Bani-Sadr F; Garraffo R; Roger PM; Treger M; Jovelin T; Pugliese P; Rey D;
PLoS One; 2016; 11(10):e0164240. PubMed ID: 27798641
[TBL] [Abstract][Full Text] [Related]
25. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
26. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
Gutierrez-Valencia A; García C; Viciana P; Milanés-Guisado Y; Fernandez-Magdaleno T; Espinosa N; Pasquau J; López-Cortés LF
PLoS One; 2018; 13(9):e0203452. PubMed ID: 30235244
[TBL] [Abstract][Full Text] [Related]
27. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
[TBL] [Abstract][Full Text] [Related]
28. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
29. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
[TBL] [Abstract][Full Text] [Related]
30. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Ward D; Zhao HH; Ross LL; Shaefer MS;
HIV Clin Trials; 2012; 13(5):233-44. PubMed ID: 23134624
[TBL] [Abstract][Full Text] [Related]
31. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
32. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Colella E; Ridolfo AL; Galli M; Rusconi S
Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
[TBL] [Abstract][Full Text] [Related]
33. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
34. Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
BMC Infect Dis; 2009 Sep; 9():154. PubMed ID: 19751502
[TBL] [Abstract][Full Text] [Related]
35. Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
Hamada Y; Nishijima T; Komatsu H; Teruya K; Gatanaga H; Kikuchi Y; Oka S
PLoS One; 2013; 8(7):e69845. PubMed ID: 23875004
[TBL] [Abstract][Full Text] [Related]
36. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
[TBL] [Abstract][Full Text] [Related]
37. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Lataillade M; Chiarella J; Yang R; DeGrosky M; Uy J; Seekins D; Simen B; St John E; Moreno E; Kozal M
PLoS One; 2012; 7(2):e30118. PubMed ID: 22355307
[TBL] [Abstract][Full Text] [Related]
38. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
39. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.
de Lastours V; Ferrari Rafael De Silva E; Daudon M; Porcher R; Loze B; Sauvageon H; Molina JM
J Antimicrob Chemother; 2013 Aug; 68(8):1850-6. PubMed ID: 23599359
[TBL] [Abstract][Full Text] [Related]
40. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
Valer L; González de Requena D; de Mendoza C; Martin-Carbonero L; González-Lahoz J; Soriano V
AIDS Patient Care STDS; 2004 Jan; 18(1):1-6. PubMed ID: 15006188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]